Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 309 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: VIGAMOX Clear all

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tuberculosis
Interventions: Moxifloxacin, PA-824, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: 1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Community-acquired Bacterial Pneumonia
Interventions: Solithromycin, Moxifloxacin, Placebo to match solithromycin; Drug · Other
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Glendale, California • Los Angeles, California • Mission Hills, California + 18 more

Conditions: Schizophrenic Disorders
Interventions: LY2140023, Placebo, Moxifloxacin; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 8
States / cities: Garden Grove, California • San Diego, California • North Miami, Florida + 5 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-955176, Placebo (Part 1), BMS-955176, Moxifloxacin, Placebo (Part 2); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744, GSK1265744 matching placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cardiac Repolarization in Healthy Subjects
Interventions: Carbidopa capsule, Moxifloxacin Tablets, USP, Placebo; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Bacterial Conjunctivitis
Interventions: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Month and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Healthy Subjects
Interventions: Venlafaxine, Moxifloxacin, Drug - placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Participants
Interventions: Aficamten, Aficamten-matching Placebo, Moxifloxacin; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Bronchitis, Sinusitis, Urinary Tract Infections
Interventions: Fluoroquinolone (FQ), Azithromycin (AZ), Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 239,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Schizophrenia
Interventions: SEP363856 150 mg, Placebo, moxifloxacin 400 mg; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 7
States / cities: Little Rock, Arkansas • Long Beach, California • Pico Rivera, California + 4 more

Conditions: Cataract Extraction
Interventions: Moxifloxacin 0.5% ophthalmic solution, Besifloxacin 0.6% ophthalmic suspension; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: tucatinib, placebo, moxifloxacin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Tuberculosis, Pulmonary
Interventions: moxifloxacin (with isoniazid, rifampin, pyrazinamide); Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 13 more

Conditions: Healthy Volunteers
Interventions: Omadacycline, Vancomycin Pill, Moxifloxacin; Drug
Lead sponsor: University of Houston; Other
Eligibility: 18 Years to 40 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: sotagliflozin, oral contraceptive, oral contraceptive + sotagliflozin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 2
States / cities: Evansville, Indiana • Dallas, Texas

Conditions: Contraceptive Usage, Overweight or Obesity, Body Weight Changes, Appetitive Behavior, Eating Behavior
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Healthy
Interventions: Ponesimod Placebo, Moxifloxacin Placebo, Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg, Ponesimod 60 mg, Ponesimod 80 mg, Ponesimod 100 mg, Moxifloxacin 400 mg; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy Subjects
Interventions: Placebo, mirabegron, moxifloxacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Contraception Behavior
Interventions: Ethinyl Estradiol / Norgestimate Oral Tablet; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Years to 23 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers
Interventions: Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Appendicitis
Interventions: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 25
States / cities: Sylmar, California • Torrance, California • Aurora, Colorado + 14 more

Search by objective public record fields.

A Phase 1 QT Study in Healthy Male Subjects

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

AL-15469A for the Treatment of Bacterial Conjunctivitis

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Fluoroquinolone Associated Disability

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

Study of Ocular Penetration of Topically Administered Fluoroquinolones

Effects of Tucatinib on Cardiac Repolarization in Healthy Participants

TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment

Microbiome Effect of Omadacycline on Healthy Volunteers

Oral Contraceptive DDI Study

A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

Premature Discontinuation of Contraceptive Implants

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial